Sofia E. Weiler

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

Journal: International journal of cancer

Published: March 13, 2025

The Cell Polarity Protein MPP5/PALS1 Controls the Subcellular Localization of the Oncogenes YAP and TAZ in Liver Cancer.

The Cell Polarity Protein MPP5/PALS1 Controls the Subcellular Localization of the Oncogenes YAP and TAZ in Liver Cancer.

Journal: International journal of molecular sciences

Published: December 06, 2024

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer.

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer.

Journal: International journal of molecular sciences

Published: June 28, 2024

SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling.

SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling.

Journal: Cancer letters

Published: September 12, 2023

Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication.

Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication.

Journal: Cellular and molecular life sciences : CMLS

Published: July 31, 2023

α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.

α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.

Journal: Cell communication and signaling : CCS

Published: January 19, 2023

Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma.

Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 11, 2022

HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1.

HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1.

Journal: Cancers

Published: January 04, 2022

Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.

Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.

Journal: Hepatology (Baltimore, Md.)

Published: December 21, 2021

Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.

Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.

Journal: BMC cancer

Published: July 14, 2021

YAP-induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer.

YAP-induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: February 28, 2021

Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.

Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.

Journal: Cell communication and signaling : CCS

Published: March 10, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026